Leveraging AI to Accelerate the Path From Diagnosis to CureCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 23, 2021 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced that it has been awarded the Health-i Award, which recognizes companies that are transforming healthcare in Germany and beyond. The Health-i Awards are sponsored by the Techniker Krankenkasse, Germany’s largest German public health insurance provider, and Handelsblatt, one of the leading business newspapers in Germany. The Health-i Award winners were selected by industry and research experts for initiatives that are transforming the next era of healthcare through innovation. CENTOGENE was awarded the prize based on its proprietary, AI-powered biomarker platform, CentoMetabolome. The internally deployed platform has the potential to revolutionize the detection of new biomarkers – accelerating research that previously took months to perform into just a few days. The use cases for the CentoMetabolome platform include supporting full metabolome screening, identifying biomarker candidates, and establishing a better understanding of drug efficacy. “We are proud to be recognized for our impact in the healthcare industry and the innovation we are bringing with our unique leading metabolomics platform,” said Carsten Ullrich, Ph.D., Senior Director of Artificial Intelligence. “Working together across several departments, we have been able to fully leverage CENTOGENE’s expertise in omics, extensive global insights from our rare disease-centric Bio/Databank, and advanced AI tools. As a result, we can now analyze the dynamics of diseases to drive biomarker discovery and test drug candidates as we continue our mission to enable the cure of 100 rare diseases in 10 years.” The continued development of AI initiatives, like CentoMetabolome, represent another significant step forward for CENTOGENE’s mission to enable the cure of 100 rare diseases within the next 10 years. To learn more, visit: https://www.centogene.com/virtual-investor-event About CENTOGENE CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical, genetic, and multiomic data to diagnose, understand, and treat rare diseases. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge and data. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository of over 600,000 patients representing over 120 different countries. The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, as well as a biobank of patients’ blood samples and cell cultures. CENTOGENE believes this represents the only platform focused on comprehensive analysis of multi-level data to improve the understanding of rare hereditary diseases. It allows for better identification and stratification of patients and their underlying diseases to enable and accelerate discovery, development, and access to orphan drugs. As of December 31, 2020, the Company collaborated with over 30 pharmaceutical partners. Follow us on LinkedIn Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws. Statements contained herein that are not clearly historical in nature are forward-looking, and the words “anticipate,” “believe,” “continues,” “expect,” “estimate,” “intend,” “project,” and similar expressions and future or conditional verbs such as “will,” “would,” “should,” “could,” “might,” “can,” and “may,” are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause CENTOGENE’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates, our ability to streamline cash usage, our requirement for additional financing and our ability to continue as a going concern, or other factors. For further information on the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to CENTOGENE’s business in general, see CENTOGENE’s risk factors set forth in CENTOGENE’s Form 20-F filed on April 15, 2021, with the Securities and Exchange Commission (the “SEC”) and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and CENTOGENE’s specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise. Media Contact: CENTOGENE Ben Legg Corporate Communications Ben.Legg@centogene.com Lennart Streibel Investor Relations Investor.Relations@centogene.com Stern IR Brendan Payne+1 (212) 698 8695brendan.payne@sternir.com